ORBIMED ADVISORS LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-13 5:20 pm Unchanged |
2023-12-11 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 4.200% |
0 (Unchanged) |
Filing |
| 2022-11-07 4:25 pm Unchanged |
2022-11-03 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 4.600% |
0 (Unchanged) |
Filing |
| 2020-11-20 4:32 pm Unchanged |
2020-11-19 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 5.500% |
0 (Unchanged) |
Filing |